Trial Profile
A trial to evaluate the oral disposition of two compounds belonging to the biopharmaceutical Classification System Class II, fenofibrate (bile salt dependent solubility) and posaconazole (gastric pH dependent dissolution), before and after RYGB in the same individuals.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2016
Price :
$35
*
At a glance
- Drugs Fenofibrate (Primary) ; Posaconazole (Primary)
- Indications Aspergillosis
- Focus Pharmacokinetics
- 11 Jul 2016 New trial record
- 01 Jul 2016 Results published in the British Journal of Clinical Pharmacology